The nurse is providing teaching for the family of a patient who has been newly diagnosed with Alzheimer disease (AD). Which statement by the family member indicates understanding of the teaching?

A) They increase norepinephrine at the neuromuscular junction: Anticholinergic agents do not directly increase norepinephrine at the neuromuscular junction. Instead, they work by blocking acetylcholine receptors (specifically muscarinic receptors) in the parasympathetic nervous system, which reduces parasympathetic activity. Norepinephrine is primarily involved in the sympathetic nervous system, not the action of anticholinergics.

B) They act to block the effects of the parasympathetic nervous system: This is the correct explanation. Anticholinergic agents work by inhibiting the action of acetylcholine at muscarinic receptors, which are part of the parasympathetic nervous system. By blocking these receptors, anticholinergics reduce parasympathetic effects such as slowing of the heart rate, increased glandular secretions, and smooth muscle contraction, leading to effects like increased heart rate, dry mouth, and bronchodilation.

C) They compete with serotonin for muscarinic acetylcholine receptor sites: Anticholinergic drugs do not interact with serotonin receptors. They specifically target muscarinic acetylcholine receptors, which are involved in parasympathetic responses. Serotonin is a different neurotransmitter, and while some drugs may affect both serotonin and acetylcholine pathways, anticholinergic agents do not compete with serotonin at these receptor sites.

D) They block nicotinic receptors: Anticholinergics typically block muscarinic receptors, not nicotinic receptors. Nicotinic receptors are involved in the transmission of signals at the neuromuscular junction and in the autonomic ganglia, while muscarinic receptors are primarily involved in parasympathetic functions. Blocking nicotinic receptors would have different effects and is not the action of anticholinergic agents.

A) Suspect worsening of the anxiety disorder:
While it is possible that the patient's anxiety disorder is worsening, the more likely explanation for the reduced effectiveness of lorazepam is the development of drug tolerance. Over time, patients may require higher doses of a medication to achieve the same therapeutic effect, especially with medications like lorazepam that are used chronically.

B) Contact the provider to discuss changing to another benzodiazepine:
Changing to another benzodiazepine might be an option, but it is more likely that tolerance to lorazepam is the cause of the reduced effect, not an issue with the specific drug. Tolerance is common with long-term use of benzodiazepines, and switching drugs may not address the underlying issue. The first step would be to assess the current medication regimen and discuss possible adjustments with the provider.

C) Understand that the patient has developed tolerance to this drug:
Tolerance occurs when the body becomes accustomed to the effects of a medication over time, requiring higher doses to achieve the same therapeutic effect. This is a common phenomenon with benzodiazepines like lorazepam, which are often used for long periods to manage anxiety. As the patient has been taking lorazepam for six months, this reduced effectiveness is likely due to the development of tolerance, rather than a worsening of the anxiety disorder.

D) Notify the provider and discuss increasing the dose of lorazepam:
While increasing the dose of lorazepam could temporarily relieve symptoms, it is not the most appropriate first step. The nurse should first consider the possibility of tolerance and discuss this with the provider before increasing the dose. Long-term increases in benzodiazepine dosages can increase the risk of side effects, dependency, and withdrawal symptoms.